$EMMA News

Last published 2mo ago

2mo agoEMMAEmmaus Life Sciences Reports Quarterly Financial ResultsBusiness WireEmmaus Life Sciences, Inc. (OTCQB:EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and
6mo agoEMMAEmmaus Life Sciences Reports Quarterly Financial ResultsBusiness WireEmmaus Life Sciences, Inc. (OTCQB:EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for
7mo agoEMMAEmmaus Life Sciences Reports Annual Financial ResultsBusiness WireEmmaus Life Sciences, Inc. (OTCQB:EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for
10mo agoEMMAEmmaus Life Sciences Announces Strategic TransactionBusiness WireEnters into North American License and Exclusive Distribution Agreement Emmaus Life Sciences, Inc. (OTCQB:EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today
3y agoEMMAEmmaus Life Sciences Receives Endari® Marketing Authorization from the Bahrain NHRAPR NewswireTORRANCE, Calif., May 31, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX:EMMA), a leader in sickle cell disease treatment, announced today that it has received a Medicine Registration Certificate (DRN-10164/23)
3y agoEMMAEmmaus Life Sciences Reports Q1 2023 Financial Results and Provides Business UpdatePR NewswireTORRANCE, Calif., May 15, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX:EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial
3y agoEMMAEmmaus Life Sciences Provides Interim Shipment DataPR NewswireTORRANCE, Calif., April 3, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX:EMMA), a leader in sickle ell disease treatment, announced today preliminary results for the 3 months ended March 31, 2023.
3y agoEMMAEmmaus Life Sciences Reports 2022 Financial Results and Provides Business UpdatePR NewswireTORRANCE, Calif., March 31, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX:EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported its results of
3y agoEMMADr. Niihara Meets with Local Indian GovernorPR NewswireCites Large, Unserved Needs of Sickle Cell Disease Patients TORRANCE, Calif., Dec. 20, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX:EMMA), announced today that Dr. Yutaka Niihara, Chairman and Chief Executive
3y agoEMMADr. Niihara Feted by Indian Government in Recognition of the Development of Endari®PR NewswireCelebrity Event Hosted in Mumbai, India TORRANCE, Calif., Dec. 19, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX:EMMA), announced today that Dr. Yutaka Niihara, Chairman and Chief Executive Officer of the
3y agoEMMAEndari® Receives Kuwaiti Marketing AuthorizationPR NewswireKuwait is Third Gulf Cooperation Council Country to Approve Endari® TORRANCE Calif., Dec. 7, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX:EMMA), a leader in sickle cell disease treatment, announced today
3y agoEMMAEmmaus Life Sciences Receives Endari® Marketing Authorization from the Qatar Ministry of Public HealthPR NewswireCompany Receives First Major Purchase Order in Saudi Arabia TORRANCE, Calif., Nov. 17, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB:EMMA), a leader in sickle cell disease treatment, announced today that it has
3y agoEMMAEmmaus Life Sciences Reports Q3 2022 Financial Results and Provides Business UpdatePR NewswireTORRANCE, Calif., Nov. 14, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX:EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its results of
4y agoEMMAEmmaus Life Sciences Announces Collaboration with Kier (Junior) Spates to Share Personal Experience with Sickle Cell Disease and Endari®PR NewswireNationally Syndicated Radio Programming Will Educate and Support SCD Patients TORRANCE, Calif., Sept. 28, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX:EMMA) a commercial-stage biopharmaceutical company and leader in the treatment of sickle c
4y agoEMMAEmmaus Life Sciences Reports Q2 2022 Financial Results and Provides Business UpdatePR NewswireTORRANCE, Calif., Aug. 15, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX:EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported financial results for the three and six months ended
4y agoEMMAEmmaus Life Sciences Announces Engagement of Strategic Business Relations and Professional Services AdvisorPR NewswireAcorn Management Partners Will Develop and Implement a Market Awareness Program Targeting Financial Professionals TORRANCE, Calif., July 12, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX:EMMA), a commercial-stage biopharmaceutical company an
4y agoEMMAEmmaus Life Sciences Reports Q1 2022 Financial Results and Provides Business UpdatePR NewswireTORRANCE, Calif., May 13, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX:EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported financial results for the three months ended March 31
4y agoEMMAEmmaus Life Sciences to Present at Investor Conferences in MayPR NewswireTORRANCE, Calif., April 26, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX:EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced participation in the following investor confe
4y agoEMMAEmmaus Life Sciences Announces Launch of Full-Service Telehealth SolutionPR NewswirePlatform Providers Will Handle On-line Prescribing, Dispensing and Delivery of Endari® TORRANCE, Calif., April 11, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTQXC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatme
4y agoEMMAEmmaus Life Sciences Presented Positive Real-World Data on the Efficacy of Endari® in Preventing Acute Complications from Sickle Cell Disease at the 62nd Annual Scientific Meeting of the British Society for HaematologyPR NewswireSickle Cell Patients Treated With Endari® had Statistically Significantly Fewer Vaso-Occlusive Events and Hospitalizations Through 72 Weeks Follow-up, Versus Baseline Adverse Events Among These Patients from French Guiana and Qatar were Few and Mild
4y agoEMMAEmmaus Life Sciences Reports 2021 Financial Results and Provides Business UpdatePR NewswireTORRANCE, Calif., March 31, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX:EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported financial results for the year ended December 31, 2
4y agoEMMAEmmaus Life Sciences Announces Endari® To Be Added to the Florida Medicaid Preferred Drug ListPR NewswireFlorida Joins Other States in Eliminating the Need for Prior Authorization for Medicaid Patients TORRANCE, Calif., March 29, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in the treatment of sickle cell disease, announced tod
4y agoEMMAEmmaus Life Sciences Receives U.A.E. Marketing Authorization for Endari®PR NewswireTORRANCE, Calif., March 23, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX:EMMA) a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced the approval of its application for marketing auth
4y agoEMMAEmmaus Life Sciences' Real World Data on Endari® Accepted for E-Poster at the 62nd Annual Scientific Meeting of the British Society for HaematologyPR NewswireTORRANCE, Calif., March 4, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX:EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that real world data on Endari®, the company's p
4y agoEMMAEmmaus Life Sciences to Present at the H.C. Wainwright BioConnect ConferencePR NewswireTORRANCE, Calif., Jan. 4, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX:EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that Yutaka Niihara, M.D., M.P.H, Chairman and Chie
4y agoACOGF BABYF EMMA JNHMF+8Life Sciences Companies Investor Presentations Now Available for On-Demand ViewingPR NewswireNEW YORK, Dec. 20, 2021 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the December 16th Life Sciences Virtual Investor Conference are now available for on-de
4y agoEMMAEmmaus Life Sciences Presents Positive Transfusion Data from a Post-Hoc Analysis of its Phase 3 Clinical Study of Endari® in Patients With Sickle Cell Disease at the 63rd American Society of Hematology (ASH) Annual MeetingPR NewswireTORRANCE, Calif., Dec. 14, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX:EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced positive transfusion data from a post-hoc analysis
4y agoACOGF BABYF EMMA HMTXF+7Life Sciences Virtual Investor Conference: Company Executives Present Live December 16thPR NewswireNEW YORK, Dec. 9, 2021 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, announced the agenda for its quarterly event for public and private companies, investors, and industry professionals from around the
4y agoEMMAEmmaus Life Sciences to Webcast Live at Life Sciences Investor Forum on December 16thPR NewswireTORRANCE, Calif., Dec. 9, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX:EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that Yutaka Niihara, M.D., M.P.H., Chairman and Ch
4y agoEMMAEmmaus Life Sciences' Data on Endari® Accepted for Poster Presentation at the 63rd American Society of Hematology Annual Meeting & ExhibitionPR NewswireTORRANCE Calif., Dec. 6, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX:EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that data on Endari®, the company's prescription L
5y agoEMMAEmmaus Life Sciences Reports Third Quarter Financial Results and Business HighlightsPR NewswireTORRANCE, Calif., Nov. 12, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX:EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported financial results for the quarter and nine months en
5y agoEMMAEmmaus Life Sciences Announces Partnership with UpScript to Provide Telehealth Solutions to Sickle Cell Disease PatientsPR NewswireTORRANCE, Calif., Nov. 11, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX:EMMA) a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced a partnership with UpScript IP Holdings, LLC. (UpSc
5y agoAAZZF ABIO ACOGF ACST+81Investor Summit Group Provides Update on Upcoming Q4 Virtual SummitGlobeNewswireNEW YORK, Nov. 05, 2021 (GLOBE NEWSWIRE) -- The Investor Summit Group, widely recognized for its reputation as the host of North America's largest independent investor conferences, will be hosting the upcoming Q4 Virtual Summit on November 16-17. The e
5y agoEMMAEmmaus Life Sciences Enters into Agreement with Asembia to Provide Expanded Patient Support ServicesPR NewswireTORRANCE, Calif., Nov. 4, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX:EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced it has entered into an agreement with Asembia to pro
5y agoEMMAEmmaus Life Sciences Submits Application for U.A.E. Marketing Authorization for Endari®PR NewswireTORRANCE, Calif., Oct. 26, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC:EMMA) a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced the submission of its application for m
5y agoEMMAEmmaus Life Sciences Acquires Key Intellectual Property Rights to Novel IRAK4 Inhibitor From Kainos MedicinePR NewswireTORRANCE, Calif., Oct. 12, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX:EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced the signing of an agreement with Kainos
5y agoEMMA OTCMOTC Markets Group Welcomes Emmaus Life Sciences, Inc. to OTCQXPR NewswireNEW YORK, Sept. 8, 2021 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX:OTCM), operator of financial markets for 11,000 U.S. and global securities, today announced Emmaus Life Sciences, Inc. (OTCQX:EMMA), a commercial-stage biopharmaceutical company, has
5y agoEMMAEmmaus Life Sciences Reports Financial Results for the Six Months Ended June 30, 2021PR NewswireTORRANCE, Calif., Sept. 2, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC:EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced financial results for the six months ended June 30, 2
5y agoEMMAEmmaus Life Sciences Announces Bahrain Temporary License of Endari®PR NewswireTORRANCE, Calif., Aug. 17, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC:EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today that on August 12, 2021, the National Health Regulato
5y agoEMMAEmmaus Life Sciences Provides SEC Reporting UpdatePR NewswireTORRANCE, Calif., Aug. 10, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC:EMMA), a leader in sickle cell disease treatment, announced today that it has restated its financial statements for the fiscal year ended December 31, 2020,
5y agoEMMATexas Adds Endari® to Latest Preferred Drug ListPR NewswireTORRANCE, Calif., Aug. 2, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC:EMMA), a leader in the treatment of sickle cell disease, announced today that Endari® has been included on the Preferred Drug List published on July 29, 2021, by Texas Healt
5y agoEMMAEmmaus Life Sciences Provides Interim Sales InformationPR NewswireTORRANCE, Calif., July 22, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC:EMMA), a leader in sickle cell disease treatment, announced today preliminary sales results for the six months ended June 30, 2021.
5y agoEMMAEmmaus Life Sciences Announces Submission of Endari® Marketing Authorization Application in KuwaitPR NewswireTORRANCE, Calif., July 15, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC:EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today the submission of its application for Marketing Autho
5y agoEMMAEmmaus Life Sciences Announces Submission of Marketing Authorization Application to Swissmedic Ideogen, A.G. to Manage Early Access ProgramPR NewswireTORRANCE, Calif., June 15, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC:EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today it has received confirmation from the Swiss Agency f
5y agoEMMAEmmaus Life Sciences Announces Submission of Marketing Authorization Application for Endari® to the Saudi Food & Drug AuthorityPR NewswireTORRANCE, Calif., May 26, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC:EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today that its application for Marketing Authorization (MA
5y agoEMMAEmmaus Life Sciences Reports Annual Financial Results for 2020 and Provides Updated Business ReviewPR NewswireTORRANCE, Calif., May 4, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC:EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today its financial results for the year ended December 31, 2
7y agoEMMAEmmaus Life Sciences to be Delisted from Nasdaq Stock Market Following HearingPR NewswireEmmaus Life Sciences, Inc. (Nasdaq: EMMA), a leader in sickle cell disease treatment, announced today that it was informed yesterday that the Nasdaq...
7y agoEMMAEmmaus Life Sciences Granted European Patent for use of Pharmaceutical-grade L-glutamine in Treating DiverticulosisPR NewswireEmmaus Life Sciences, Inc. (Nasdaq: EMMA), a leader in sickle cell disease treatment, announced today the allowance of patent application number...
7y agoEMMAEmmaus Life Sciences Adds Oncology Supply as DistributorPR NewswireEmmaus Life Sciences, Inc. (Nasdaq: EMMA), a leader in sickle cell disease treatment, announced today the addition of Oncology Supply, a part of...
7y agoEMMAEmmaus Life Sciences to Host "Sideline Sickle Cell" Community Town Hall with ASAP and FSCDR in South FloridaPR NewswireEmmaus Life Sciences, Inc. (Nasdaq: EMMA), a leader in sickle cell disease treatment, announced today that the company's Sideline Sickle Cell...